Showing 121 - 140 results of 114,913 for search '(( a non decrease ) OR ( 5 ((((nn decrease) OR (point decrease))) OR (a decrease)) ))', query time: 1.51s Refine Results
  1. 121
  2. 122
  3. 123
  4. 124

    Different response of visASCs to a micro-local oxygen concentration decrease in metabolically active sites of the adipose tissue. by Wilfredo Oliva-Olivera (301968)

    Published 2017
    “…However, hypox-visASCs from MS patients show a lower ability to actively participate in or stimulate the formation of microvascular structures, while they favor the accumulation of CD11C<sup>+</sup> and CD163<sup>+</sup> macrophages in the adipose tissue through their contribution to the increased tissue levels of MCP1. ↑ Increased response; <b>↓</b> Decreased response; → Hypox-visASCs main response NonMS: obese subjects without metabolic syndrome; MS: obese subjects with metabolic syndrome; visASC: visceral adipose tissue-derived multipotent mesenchymal cells; hypox-visASCs: visASC under hypoxia; NOX5: NADPH Oxidase 5; SDF1α: stromal cell-derived factor 1α; VEGF: vascular endothelial growth factor; MCP1: monocyte chemoattractant protein 1; CD11C<sup>+</sup>, CD163<sup>+</sup>: proinflammatory macrophage cell-surface markers.…”
  5. 125
  6. 126

    <i>Ext1</i> mutant lungs exhibit a decrease in SHH-FGF10 signaling. by Hua He (120374)

    Published 2017
    “…<p>(A) qPCR analysis of key components of FGF signaling pathway in lungs from E14.5. …”
  7. 127

    Image_5_miR-144-5p and miR-451a Inhibit the Growth of Cholangiocarcinoma Cells Through Decreasing the Expression of ST8SIA4.tif by Wan Fu (3681799)

    Published 2021
    “…This study aimed to investigate the action mechanism of miR-144-5p and miR-451a in cholangiocarcinoma. We found that miR-144-5p and miR-451a were significantly decreased in cholangiocarcinoma patient samples compared to the adjacent normal bile duct samples. …”
  8. 128
  9. 129
  10. 130

    mGluR5 receptor decreased glycinergic currents. by Zi-Yang Zhang (4988555)

    Published 2019
    “…<p>(<b>A–B</b>) Bath perfusion of DHPG for 3 min reduced GlyR-IPSCs (<b>A</b>; 70.2 ± 4.2% of baseline at 15–20 min post-DHPG, <i>t</i>[16] = 6.707, <i>p</i> < 0.001, paired Student <i>t</i> test), but not GABA<sub>A</sub>-receptor–mediated IPSCs (<b>B</b>; 102.9 ± 3.3% of baseline at 15–20 min post-DHPG, <i>t</i>[5] = 0.347, <i>p</i> = 0.743) in spinal slices of mice. …”
  11. 131
  12. 132
  13. 133

    Vectorized siRNA TMPRSS2-ERG IV-SQ impaired tumour growth and restored differentiation <i>in vivo</i>. by Giorgia Urbinati (554921)

    Published 2015
    “…<p><b>a.</b> SCID mice (n = 5/group) bearing VCaP tumour xenografts were injected intravenously either with NaCl 0.9%, non-vectorized siRNA TMPRSS2-ERG IV, NPs siRNA control-SQ or NPs siRNA TMPRSS2-ERG IV-SQ twice per week during 6 weeks (1.8 mg/kg/mouse cumulative dose). …”
  14. 134

    Table_1_v2_A long waiting time from diagnosis to treatment decreases the survival of non-small cell lung cancer patients with stage IA1: A retrospective study.docx by Bin Liu (5899)

    Published 2022
    “…After adjusting for other confounders, the waiting time was identified as an independent prognostic factor.</p>Conclusions<p>A long waiting time before treatment may decrease the survival of stage IA1 NSCLC patients. …”
  15. 135
  16. 136

    Low concentrations of siRNA TMPRSS2-ERG III and IV impair TMPRSS2-ERG oncogene and oncoprotein levels but not cell viability. by Giorgia Urbinati (554921)

    Published 2015
    “…<b>a. RT-qPCR analysis:</b> relative TMPRSS2-ERG fusion variants III and IV mRNA levels were analysed and compared to non-treated cells. …”
  17. 137
  18. 138
  19. 139

    Proteasome activity was decreased in the <i>myc-rpt6-S119A</i> mutant. by Esther Magdalena Marquez-Lona (4183126)

    Published 2017
    “…<p>(A) Lysates from strains in stationary phase (A<sub>600</sub>>5.0) were subjected to native gel electrophoresis followed by an in-gel activity assay with the fluorogenic proteasome substrate Suc-LLVY-AMC. …”
  20. 140

    Efficacy of an herbal compound in decreasing steatosis and transaminase activities in non-alcoholic fatty liver disease: A randomized clinical trial by Seyyed Abbas Zojaji (5208589)

    Published 2022
    “…<div><p>Abstract Hepatoprotective effects of many herbal agents have been reported in animal studies and clinical trials. In this study, five hepatoprotective plants with potent antioxidant, anti-inflammatory, and hypolipidemic effects were chosen to prepare a polyherbal compound for managing NAFLD. …”